ClinicalTrials.gg
Drug

Navitoclax clinical trials

Also written ABT-263 and A-855071.0.

studies test it
37
open now
1
in phase 3
2
first study started
2006

How each study uses navitoclax is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the navitoclax studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Navitoclax
24
BcI-2 Family Protein Inhibitor ABT-263
7

Development codes

ABT-263
32
A-855071.0
7

Studies by the year they started

37 studies that test it; most in 2009 (8)

Studies that test navitoclax, by start year
YearStudies
20061
20072
20081
20098
20104
20111
20121
20131
20141
20151
20162
20172
20181
20191
20202
20211
20224
20232
20241

Who runs them

Industry 23 · Other 14

AbbVie (11) · National Cancer Institute (NCI) (5) · AbbVie (prior sponsor, Abbott) (5) · Abbott (5) · Genentech, Inc. (2) · St. Jude Children's Research Hospital (1) · City of Hope Medical Center (1) · Jacqueline Garcia, MD (1)

Often tested with

Tested in the same studies.

Venetoclax (8) · Decitabine (3) · Ruxolitinib (2) · Antineoplastic Agents (1) · Erlotinib (1) · Irinotecan (1) · Rituximab (1) · Vistusertib (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test navitoclax.

Studies

Open first, then newest update. How each study uses navitoclax is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 37

See all 37 studies that test navitoclax →

Given beside what is tested · 6 — navitoclax is usual care or a partner of the new treatment

Codes

What other systems call navitoclax · ClinicalTrials.gg INT005266

  • MeSH (NLM) C528561navitoclaxConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) XKJ5VVK2WDNAVITOCLAXConfirmed FDA, NLM, Wikidata
  • Wikidata Q18002993navitoclaxConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C64776NavitoclaxOne source FDA
  • DrugBank DB12340One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.